Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Emily K. Ninmer
Observed names:
E.K. Ninmer,
Emily K Ninmer,
Emily Ninmer,
Ninmer, Emily
Institutions:
University of Virginia Health System,
University of Virginia Medical Center,
University of Virginia Cancer Center,
University of Virginia
Observed institutions:
University of Virginia Health System,
University of Virginia Medical Center,
University of Virginia Cancer Center,
University of Virginia
ORCID:
0009-0001-2973-9883
Observed ORCID:
0009-0001-2973-9883
OpenAlex ID:
A5021172079
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial
2024
·
Emily K. Ninmer
, Hong Zhu
, et al.
·
Nature Communications
·
40
PDF
Adenoviral Respiratory Infection-Associated Mortality in Children: A Retrospective Case Series
2020
·
Michael C. Spaeder
, Claire Stewart
, et al.
·
Journal of Pediatric Intensive Care
·
11
The Landmark Series: Cancer Vaccines for Solid Tumors
2024
·
Emily K. Ninmer
, Feifan Xu
, et al.
·
Annals of Surgical Oncology
·
10
PDF
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)
2026
·
Emily K Ninmer
, Gina R Petroni
, et al.
·
Journal for ImmunoTherapy of Cancer
·
6
PDF
Methotrexate Monitoring in Dermatology— A Retrospective Cohort Study
2021
·
Alina Zufall
, Bharath Rama
, et al.
·
Journal of Drugs in Dermatology
·
5
Twenty‐year survival outcomes after multipeptide vaccination for resected high‐risk melanoma: A post‐hoc analysis of a randomized clinical trial
2025
·
Emily K. Ninmer
, Hong Zhu
, et al.
·
International Journal of Cancer
·
4
PDF
1466 Phase I/II clinical trial of a melanoma vaccine targeting shared nonmutated antigens and a shared mutated neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR agonist (polyICLC)
2024
·
Emily K Ninmer
, Gina R Petroni
, et al.
·
Journal for ImmunoTherapy of Cancer
·
3
Evaluating the Vascular Quality Initiative’s role in advancing minority health and health disparities research—A scoping review
2025
·
G. Finn Repella
, Emily K. Ninmer
, et al.
·
Journal of Vascular Surgery
·
2
PDF
Gender differences in operative feedback for vascular surgery trainees
2025
·
M. Libby Weaver
, Ting Sun
, et al.
·
JVS-Vascular Insights
·
2
626 Long-term outcomes of a randomized trial of two multipeptide melanoma vaccines (Mel39) suggests outcome differences based on participant sex
2023
·
Emily K Ninmer
, Craig L Slingluff
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
A phase II pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma, with sequential evaluation of the tumor microenvironment
2026
·
Craig L. Slingluff
, Marc S. Ernstoff
, et al.
·
Cancer Immunology Immunotherapy
Table 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S3 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S6 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Figure S1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S2 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Supplementary File 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S4 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S10 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Data from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Figure S2 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Figure 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Figure 4 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S8 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Show more works
View as search
Works count:
57
Citation count:
84
H-index:
5
I10-index:
3
Year
Topic
Type